Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5890647 | 0.86 | CSNK1D (0.49) | CSNK1DMAPK8MAPK13MAPK12MAPK11 | |
| SCHEMBL6489239 | 0.76 | ADORA1 (0.44) | ALOX5ADORA1CSNK1DMAPK14CDK4 | |
| SCHEMBL21621292 | 0.76 | ADORA1 (0.44) | ADORA1CSNK1DMAPK8MAPK13MAPK12 | |
| SCHEMBL29947058 | 0.76 | ADORA1 (0.44) | ADORA1CSNK1DMAPK8MAPK13MAPK12 | |
| SCHEMBL5455134 | 0.70 | ALOX5 (0.44) | ALOX5ADORA1CSNK1DMAPK8MAPK14 | |
| SCHEMBL5456668 | 0.68 | MAPK14 (0.48) | ALOX5ADORA1CSNK1DMAPK8MAPK14 | |
| SCHEMBL5890920 | 0.67 | CSNK1D (0.50) | CSNK1DMAPK8MAPK13MAPK12MAPK11 | |
| SCHEMBL5216644 | 0.66 | CSNK1D (0.49) | CSNK1DMAPK8MAPK13MAPK12MAPK11 | |
| SCHEMBL5456838 | 0.66 | CSNK1D (0.51) | CSNK1DMAPK8MAPK13MAPK12MAPK11 | |
| SCHEMBL5890927 | 0.66 | CDK4 (0.49) | CSNK1DMAPK8MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | claimed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | claimed |
| US-7030134-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | GUDMUNDSSON KRISTJAN (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142941-A1 | Therapeutic compounds | PCSK9, ABCB1, ABCB11 | ALOX5 1153/4885ADORA1 277/4885CSNK1D 466/4885 |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | DPYD, TYMP, P2RY4 | ALOX5 2148/4885ADORA1 522/4885CSNK1D 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.